Evestra’s second publication which describes novel antiprogestins for the treatment of breast cancer published in the scientific peer review journal Steroids
Evestra’s first patent which covers selective progesterone modulators allowed by the EU Patent Office
Evestra’s research work to develop novel mesoprogestins published in the scientific peer review journal Steroids
Evestra pre-term birth grant proposal was selected as a finalist in the Saving Lives at Birth Grand Challenge sponsored by The Gates Foundation
Evestra announces research collaboration with Northwestern University in the area of breast cancer.
Evestra received the next license payment from corporate partner to develop and commercialize its lead product for the rest-of-the-world (ROW) market. Total payments received in 2013 is $1.3 million.
Evestra received a $1 million milestone payment for achieving the next milestone of collaboration with its partner to develop and commercialize its leading products for the EU market
For more info about 2013, please click here
© 2017 Evestra, Inc.